The U.S. Food and Drug Administration approved Pfizer’s Xalkori (crizotinib) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive.

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

Gene sequencing of more than 1,000 children and adolescents diagnosed with cancer found that as many as 8.5 percent were born with genes that increase their risk of developing cancer, […]

Boston-based Third Rock Ventures announced today it had raised $52 million to launch a company called Decibel Therapeutics to work on hearing loss.   Decibel Therapeutics will be headquartered at […]